Abstract: Glucocorticoid hormones play essential roles in adaptation to stress, regulation of metabolism and inflammatory responses. Their effects primarily depend on their binding to intracellular receptors leading to altered target gene transcription as well as on cell-type specific biotransformation between 11 -hydroxy glucocorticoids and their 11-oxo metabolites. The latter effect is accomplished by two different 11 -hydroxysteroid dehydrogenase isozymes, constituting a shuttle system between the receptor ligand cortisol and its non-binding precursor cortisone. Whereas the type 1 enzyme (11 -HSD1) is in vitro a NADP(H)-dependent bidirectional enzyme, it reduces in most instances in vivo cortisone to active cortisol. The type 2 enzyme is an exclusive NAD+ dependent dehydrogenase of glucocorticoids, thus "protecting" the mineralocorticoid receptor against illicit occupation by cortisol.
INTRODUCTION
Glucocorticoids (GCs) are steroid hormones secreted by the adrenal glands in a circadian fashion, further modulated by ectopic stress signals such as trauma, inflammation, psychological stress or physical exercise [1] [2] [3] . These hormones affect every tissue and organ in the body and thus contribute to maintain overall homeostasis and, importantly, are one of the most potent modulators of the stress response in mammals. Besides the stress mediated effects of the sympathetic nervous system on metabolic alterations that contribute to the etiology of diabetes mellitus, atherosclerosis and cardiovascular disease [4] , GCs are among the critical components identified in metabolic disease. GCs are key players to control intermediary metabolism, the maintenance of cardiovascular tone, electrolyte balance, growth, development and reproduction, to orchestrate the immune response and are among other factors involved in several functions of the central nervous system such as cognition, behaviour, mood and sleep [5, 6] .
Glucocorticoid Mechanisms
The main GCs secreted by the adrenals in man are cortisone and cortisol (dehydrocorticosterone and corticosterone in rodents), differing in the chemical function at C11 of the steroid nucleus (Fig. 1) . These chemical differences determine the biological function, with cortisol (an 11 -hydroxy steroid) being a high affinity ligand for the glucocorticoid receptors (GR), whereas cortisone, the 11-keto steroid does not bind to the receptor. GCs act via a complex pattern of interactions involving transport proteins, passage through the cell membrane, intracellular metabolism and binding to their cognate glucocorticoid receptors (GR), which are transcription factors belonging to the superfamily of nuclear receptors. These receptor-ligand complexes can specifically interact with other factors and responsive elements located in the promoter of target genes, ultimately leading to specific induction or repression of these target genes [7] . Each of these processes shows complex mechanisms that can determine a dynamic pattern of response to GCs. For instance plasma transport and binding is different for cortisone and cortisol, the latter being tightly bound to corticosteroid binding globulin (CBG), whereas cortisone is largely unbound and can freely enter the cells, an effect that determines GC bioavailability [8, 9] . On the receptor level, another layer of complexity is achieved. Cortisol has high binding affinity for both the GR and the mineralocorticoid receptor (MR) in vivo [10] [11] [12] . Due to the presence of at least 2 isozymes (type 1 and type 2 11 -hydroxysteroid dehydrogenase, 11 -HSD1 and 11 -HSD2, respectively, cf below) an extensive, tissue-specific cortisone-cortisol shuttle system is created [13] [14] [15] [16] . Due to the presence of an NADPHdependent 11-keto reductase (type 1 enzyme, 11 -HSD1) in organs such as liver or adipose tissue, rapid activation of cortisone to the GR ligand cortisol takes place. In peripheral tissues GC activation of the MR (eg kidney, salivary gland, colon) is inhibited by rapid conversion of cortisol to cortisone by an NAD+-dependent 11 -hydroxysteroid dehydrogenase (type 2 enzyme, 11 -HSD2), allowing appropriate occupancy of the MR by aldosterone, the major mineralocorticoid hormone in man. Finally, through alternative use of two terminal exons (exon 9 and 9 ) in the GR gene and through different translational start sites, the GR and GR isoforms (up to eight different isoforms per or variant are observed) display multiple quantitatively and qualitatively different tissue specific effects, thus adding another level of complexity to GC action [17, 18] .
Whereas the areas of GC transport and receptor physiology are covered in several other recent articles [2, [7] [8] [9] 17, 19] , this paper summarizes the current knowledge and perspectives of the glucocorticoid metabolizing enzyme 11 -hydroxysteroid dehydrogenase, with particular emphasis on disease mechanisms, drug development and structure-activity relationships of the type 1 enzyme. Since its inception almost 50 years ago [20] [21] [22] and the discovery of two distinct 11 -HSD forms about 15 years ago, much has been learned about the physiology and involvement in metabolic diseases for this enzyme system and since then has been covered in several excellent recent reviews [13, 15, 16, [23] [24] [25] [26] . This overview aims to summarize the recent, rapid progress achieved in the analysis of animal and cellular model systems, clinical studies, drug development programs and structural determination of the 11 -HSD1 enzyme.
Glucocorticoids and Disease
The critical role of GCs for mammalian homeostasis is clearly highlighted by the phenotypical changes observed in deficiency to produce these steroids (Addison's disease) and those observed in situations of overproduction (Cushing's disease). Adrenal insufficiency to produce GCs (caused by destruction of the adrenal gland e.g. by infection, autoimmune disorders, tumor metastases) leads to general weakness, pigmentation of the skin, weight loss and hypotension. In contrast, the systemic high levels of GCs observed in patients with Cushing's syndrome (usually with a pituitary tumor leading to overproduction of ACTH, the hormone controlling GC release and production from the adrenal gland or through pharmacological immunosuppressive treatment with synthetic GCs as in inflammatory disorders or in transplantation settings) show central obesity, insulin resistance, glucose intolerance, behavioural changes, dyslipidemia, and hypertension. The main metabolic effects of GCs in respect to the metabolic syndrome comprise (as the name implies) regulation of fasting blood glucose levels (through hepatic induction of gluconeogenesis enzymes, mainly glucose-6-phosphatase and phosphoenolpyruvate carboxykinase (PEPCK)), control of adipocyte proliferation, differentiation and metabolism, control of skeletal muscle insulin sensitivity, and regulation of insulin secretion from the -cells of the endocrine pancreas. Fig. (1) . The glucorticoid shuttle. Cortisol secreted by the adrenal gland underlies an extensive shuttle mechanism involving 11 -OH oxidation and 11-oxo reduction carried out by 11 -HSD isozymes (for details cf text). The type 1 isozyme expressed in several target tissues reduces cortisone to the GR ligand cortisone in an NADPH dependent reaction, whereas the type 2 isozyme mainly located in the kidney inactivates cortisol to cortisone. Indications for inhibition of 11 -HSD1 comprise aspects of the metabolic syndrome, cognitive dysfunction and glaucoma, whereas dysfunctions observed for 11 -HSD2 are associated with apparent mineralocorticoid excess, fetal GC exposure and possibly cancer.
The metabolic changes occurring in Cushing's disease are also observed in patients with the metabolic syndrome and constitute independent risk factors for the development of cardiovascular disease [15, [23] [24] [25] [26] , still among the most health threatening conditions in western societies and rapidly progressing in third world countries. Importantly, these symptoms are usually reversible in Cushing's disease, upon correction of the primary cause. However, despite extensive efforts, no systemic elevation of GC levels is observed in patients with the metabolic syndrome, an enigma that is solved by the discovery that the GC activating enzyme 11 -HSD1 is present in adipose tissue or liver, an effect, which locally produces elevated tissue levels of GCs, in the light of normal systemic GC levels.
Pre-Receptor Control by Metabolic Activation Through 11 -Hydroxysteroid Dehydrogenases
Subsequent to the establishment of cortisone treatment as cornerstone in chronic inflammatory diseases [20] [21] [22] , it was discovered that in fact the 11 -hydroxyl moiety in GCs is the determining factor in GR binding (and hence efficacy), a metabolic reaction catalyzed by 11 -hydroxysteroid dehydrogenase isozymes (Fig. 1) . Several in vitro and in vivo studies established a complex tissue-specific pattern of cortisone reduction and cortisol oxidation, thus establishing a shuttle between receptor binding and non-binding GCs [10, 15] . The first isozyme cloned was rat liver 11 -HSD1 [27] , a 34 kDa membrane bound, glycosylated enzyme belonging to the superfamily of short-chain dehydrogenases/reductases (SDR). SDRs constitute a large, evolutionarily conserved superfamily of oxidoreductases with substrate specificities comprising steroids, lipids, polyols or xenobiotics [28, 29] . Heterologous expression established 11 -HSD1 as an NADP(H) dependent oxidoreductase, capable of mediating in vitro the reversible oxidoreduction of GC pairs such as cortisone/cortisol [30, 31] . Later on, it was discovered that 11 -HSD1 is located within the endoplasmic reticulum (ER) through an N-terminal transmembrane helix and faces the lumen of the ER with the catalytic domain [32, 33] . The more recent discovery by Stewart's group of a distinct NADPH generating hexose-6-phosphate dehydrogenase (H6PD) system within the lumen of the ER clearly underpinned the dependence of local cofactor availability for the reaction direction of 11 -HSD1 [34] . These data explained the observed preferred reductive reaction catalyzed by 11 -HSD1 [35] [36] [37] [38] , in spite of catalyzing in vitro or in tissue homogenates the dehydrogenase reaction with high efficiency [31, 39] . Moreover the data and mutations found in the H6PD gene explained the observed cortisone reductase deficiency in patients unable to activate cortisone acetate [34, 40] . Furthermore, this model of local generation of nucleotide cofactor delivered an explanation for the differentiation dependent switch of reaction direction in glucocorticoid activation/inactivation observed for example during adipocyte development [41, 42] .
Research at the time of 11 -HSD1 discovery and cloning in the early 1990s was fueled by the discovery that defective cortisol to cortisone conversion was the underlying primary cause in the rare syndrome of apparent mineralococrticoid excess (AME). Impaired GC inactivation by 11 -OH dehydrogenation mostly in the kidney leads to hypokaliemia and severe juvenile hypertension and is associated with high mortality if remained untreated [43] [44] [45] [46] . However, no mutations were found in the HSD11B1 gene in these affected families [47] , and shortly thereafter the type 2 11 -HSD gene was cloned independently by several groups [48] [49] [50] This enzyme is strictly NAD(H) dependent [49, 51] , is bound to the ER possibly through several transmembrane helices, but in contrast to the type 1 enzyme faces the cytoplasmic space with its catalytic domain. Consequently it could indeed be shown that several mutations in this HSD11B2 in the AME patients described are causative for the disease [52] . Population studies reveal that polymorphisms within the gene are associated in part with increased salt sensitivity [53] . The expression of 11 -HSD2 in placenta and its postulated role in protection of the fetus against maternal GC exposure could constitute the link to epidemiological observations of low birthweight and adult hypertension [54] [55] [56] [57] . Due to the established role of GCs in promoting differentiation and inhibiting proliferation, an important role of 11 -HSD2 as potential oncogene was described more recently [58, 59] . Increased expression of 11 -HSD2 was noted for example in adrenal cortical adenomas, pituitary tumors, in breast and endometrial cancer and a critical role of 11 -HSD2 in invasive carcinoma was determined [58, 59] . Inhibition of 11 -HSD2 activity in several cancer cell lines potentiated the antiproliferative effects of GCs [58, 59] .
ANIMAL MODELS AND INHIBITORS SUGGEST 11 -HSD1 AS POTENTIAL DRUG TARGET IN THE METABOLIC SYNDROME
One of the most important discoveries in 11 -HSD1 research was that the enzyme functions in vivo or in cell culture primarily as reductase thus amplifying intracellular cortisol levels [35] [36] [37] [38] . This was further elegantly corroborated by the 11 -HSD1 knockout mouse (11 -HSD1 -/ -) [60] , showing that the enzyme is the sole 11-ketosteroid reductase, at least in mice. A logical translation of this concept into first clinical trials using the 11 -HSD isozyme-unselective inhibitor carbenoxolone showed that 11 -HSD inhibition indeed might lead to increased hepatic insulin sensitivity in healthy volunteers [61, 62] but also in a small set of diabetic patients. These initial analyses delivered for the first time substantial evidence that inhibition of 11 -HSD1 might be a useful strategy in the treatment of metabolic disorders such as insulin resistance and possibly obesity. The 11 -HSD1 -/ -animals are fertile, reproduce normally and exhibit a normal lifespan [60] . A diabetes-resistant phenotype is only apparent upon challenging by a high-fat diet or stress, showing attenuated responses to these stimuli, with altered glucose levels, fat accumulation and lipid profiles [60, 63, 64] . The hypothalamic-pituitary-adrenal (HPA) axis appears to be disturbed as shown by adrenal hyperplasia, indicating that cortisone reduction by 11 -HSD1 is also important in the CNS feedback control and HPA axis regulation [60, 65] . Later on, transgenic mice were created with a rat 11 -HSD1 gene under the control of the promoter of the adipocyte fatty acid binding protein 2 (aP2-11 -HSD1 mouse; [66] ), resulting in 2-3 fold elevated levels of 11 -HSD1 in visceral adipocytes. This expression level is also observed in several [67] [68] [69] [70] [71] but not all studies of obese patients [41, 42, 72, 73] , or in genetic rodent models of obesity such as the Zucker rat [61, 74] . Association studies suggest a correlation between GC metabolism and obesity markers such as body mass index or waist to hip ratio [75, 76] . A further indication for the significance of 11 -HSD1 and GCs in visceral fat accumulation is a Cushing patient case with defective peripheral cortisone to cortisol conversion, displaying a nonobese phenotype [77] . The aP2-11 -HSD1 mice have an about 2-fold concentration level of adipose tissue corticosterone compared to wild-type animals, whereas plasma GC levels are normal [66] . Importantly, these aP2-11 -HSD1 animals show the cardinal symptoms of the metabolic syndrome. They are obese, predominantly through visceral fat accumulation achieved through differen-tial GR distribution in visceral and subcateneous adipocytes, and display insulin resistance, glucose intolerance, leptin resistance, have elevated free fatty acid and triglyceride levels, and are hypertensive [66, 78] . The arterial hypertension is an effect obtained through activation of the renin-angiotensin-aldosterone system, likely driven by elevated levels of adipocyte derived angiotensinogen [66, 78] . Altered expression levels compared to controls for key molecules such as leptin, adiponectin, resistin, TNF , UCP and PPAR were observed [66, 78] . A non-obese phenotype of the metabolic syndrome but with accompanying dyslipidemia and arterial hypertension, caused by hepatic activation of the renin-angiotensin system, was achieved through hepatic overexpression of 11 -HSD1 using the apoE promoter (apoE-11 -HSD1 mouse) [79] . These animals display fatty liver and increased hepatic fatty acid synthesis and fatty acid -oxidation by upregulation of LXR and PPAR mRNA levels, resulting in impaired lipid clearance [79] . This animal line might be useful as a model system for myotonic dystrophia or metabolically obese, but normal weight individuals [79, 80] . Hepatic inhibition of 11 -HSD1 was achieved in several mouse models of insulin resistance by a first series of selective 11 -HSD1 inhibitors developed by Biovitrum in Stockholm [81] [82] [83] . Down regulation of hepatic gluconeogenetic enzymes like PEPCK and glucose 6 phosphatase was accompanied by a significant decrease of insulin and glucose levels, as well as lowered cholesterol, triglyceride and free fatty acid levels [81] [82] [83] . Accordingly, these results demonstrated that enzyme inhibition in the liver leads to improved insulin sensitivity and lipid status in the ob/ob, db/db and KKA y animal model systems used [82, 83] .
The expression of 11 -HSD1 not only in liver and adipose tissue, but also in skeletal muscle [84] [85] [86] and the endocrine pancreas [87] suggests a critical role of this GC activating system for regulation of overall insulin sensitivity. In skeletal muscle, the interplay between GR -andisoforms and the expression of 11 -HSD1 in a study using human myoblast cultures, and the potential consequences for overall insulin sensitivity were presented [84, 85] . Interestingly, insulin appears to upregulate 11 -HSD1 expression level in the presence of unidentified serum factors [84, 85] , thereby constituting a feedback control system, in contrast to the insulin effects observed on 11 -HSD1 expression levels in liver [37, 38] . Expression of 11 -HSD1 in skeletal myoblasts was associated with insulin, increased body mass index (BMI) and blood pressure [84, 85] . Taken together, these studies supported the notion that skeletal muscle 11 -HSD1 contributes to features of the metabolic syndrome and that pharmacological inhibition of 11 -HSD1 might lead to increased insulin sensitivity mediated in part by increased triglyceride uptake in skeletal muscle. The presence of 11 -HSD in pancreatic islets and -cells was first established in the ob/ob mouse system [87] . The fundamental role of GC on -cell physiology was investigated in several studies, showing that increased glucocorticoid sensitivity leads to inhibition of insulin release [88] [89] [90] . Transgenic mice, overexpressing the GR in -cells under the control of the insulin promoter show increased GC sensitivity, and animals ultimately develop diabetes with a decreased capacity in insulin secretion [88, 89] . In several cell culture systems, GCs display profound and complex effects on insulin secretion, with enhancing or inhibiting effects, depending on the experimental conditions [87] [88] [89] [91] [92] [93] . In ob/ob mice GCs inhibit insulin secretion [87, 94] , further amplified by 11 -HSD1 [87] . Blockade by CBX or synthetic selective 11 -HSD1 inhibitors such as the arylsulfonamide thiazole BVT2733 enhances glucose stimulated insulin secretion (GSIS) [87, 94] . In contrast to the ob/ob mouse model, treatment of islets derived from lean mice with 11-oxo or 11 -OH GCs results in enhancement of insulin secretion (Hult et al. unpublished data) , consistent with a role of GCs as stress hormones and 11 -HSD1 as key regulator to mediate glucose uptake and energy supply under stress conditions. These results further point to a fundamental difference in the GC status in islets from lean and obese animals. Therefore 11 -HSD1 might constitute an essential factor for the ability of the endocrine pancreas to adequately secrete insulin, and accordingly could play a role in the pathogenesis of insulin resistance.
A convincing proof of concept that 11 -HSD1 is a valid target for treatment of the metabolic syndrome was derived from animal models treated with a selective 11 -HSD1 adamantyltriazol inhibitor developed by Merck [95] [96] [97] . The compound potently inhibits 11 -HSD1 activity in liver and importantly also in adipose tissue. In diet induced obesity, the compound lowers weight gain, food intake and fat accumulation, and similar to the effects observed with other inhibitors improves insulin sensitivity and lipid profile, e.g. cholesterol, triglyceride and free fatty acid levels [97] . Furthermore, in the apoE knockout mouse, the compound dramatically reduces atherosclerotic plaque formation, and for the first time suggests direct beneficial effects of enzyme inhibition on progression of atherosclerosis and cardiovascular disease [97] . Since the lipid effects observed were mainly a moderate decrease in lipid levels, these actions on plaque formation are likely to be mediated through direct effects on the complex artheriosclerotic process [25, 97] . Importantly, 11 -HSD1 expression has been demonstrated in endothelial cells, activated macrophages and smooth muscle cells, and likely involves a yet to be defined role of 11 -HSD1 in inflammatory mediation of plaque formation [25, 97] . Taken together, all animal and pharmacological studies carried out thus far support the concept that blockade of 11 -HSD1 might be a valid, novel approach in the treatment of all facets of the metabolic syndrome.
Expression of 11 -HSD1 is Regulated by Nutritional and Hormonal Signals
Consistent with its role as a key player to orchestrate metabolic control, 11 -HSD1 itself is subject to a complex regulation by a multitude of nutritional and hormonal stimuli. Among the most important factors known to downregulate 11 -HSD1 expression and activity mostly in liver are growth hormone (GH), IGF1 and insulin [37, 38, [98] [99] [100] , whereas cytokines such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-13, TNF and IFN upregulate mRNA levels in different target tissues [73, [101] [102] [103] [104] , also pointing to a role of the enzyme in inflammatory processes. Importantly, GCs upregulate 11 -HSD1 levels in the short-term in several cell systems [37, 38, 99] , but appear to downregulate activity after longer treatment in primary hepatocyte cultures [105] . In most instances insulin and GCs show opposing effects on 11 -HSD1 expression levels, consistent with their metabolic roles. During adipocyte differentiation both hormones act synergistically, but only GCs increase expression levels of 11 -HSD1 [106] , as also observed in human myoblasts [84, 85] . Importantly, other transcription factors involved in metabolic control, such as PPAR , PPAR , C/EBP and LXR have a profound effect on 11 -HSD1 regulation. Whereas C/EBP upregulates expression [107, 108] , C/EBP , the dominant negative inhibitor of C/EBP , attenuates 11 -HSD1 expression. Moreover, the nuclear hormone receptors PPAR and , involved in fatty acid and lipid metabolism in hepatocytes and adipocytes, and the oxysterol receptor LXR, downregulate 11 -HSD1 expression in several animal and cell culture model systems [109] [110] [111] . In a study using a nonthiazolidinedione PPAR -agonist pronounced effects on depot-specific expression of 11 -HSD1 were noted, which could in part explain the insulin sensitizing effects of these compounds [112] . These differential effects on adipocyte depot (subcutaneous vs visceral) specific alterations and the adipocyte-specific developmental switch between dehydrogenase (cortisol inactivating) and reductase (cortisone activating) activities might constitute a critical factor in the pathogenesis of visceral obesity [42] . Taken together, these studies clearly show that 11 -HSD1 expression is subject to a dynamic regulation by a multitude of complex nutritional signals, allowing integration of these stimuli by controlling GC levels. Clearly further studies are warranted to investigate the effects of dietary and environmental compositions and challenges on 11 -HSD1 expression, to understand and expand the role of nutrients themselves as signals to control metabolism [113, 114] and to elucidate the role of GC amplification in these processes.
FURTHER INDICATIONS FOR SELECTIVE 11 -HSD1 INHIBITION
Besides the potential beneficial use of selective -HSD1 inhibitors to treat insulin resistance, obesity, dyslipidemia and cardiovascular disease, several studies suggest further potential applications, as outlined in the following subchapters. Some of these applications, namely the GC amplification effects by 11 -HSD1 on the CNS and in glaucoma, appear to be rather validated, whereas several others, e.g. the role of 11 -HSD1 in immunity and inflammatory processes clearly deserve further investigation and experimental efforts.
Glucocorticoids and the CNS: the Role of 11 -HSD1 in Ageing and Neurodegeneration
GCs exert a multitude of effects on the central nervous system affecting among others neurotransmitters, receptors, ion channels and metabolism [115] [116] [117] . Chronically elevated levels of GCs clearly impair neuropsychiatric functions and can lead to dysfunctions such as depression, anxiety, psychosis or euphoria. Thus considerable evidence exists which links GCs with cognitive functions and the neuroendocrine axis [115] [116] [117] . A highly sensitive site for GC effects is the hippocampus, a brain structure necessary to integrate multiple neuroendocrine, cognitive and affective signals. Expression of 11 -HSD1 in the central nervous system was shown to be mainly restricted to the hippocampus, cerebellum and the cortex [118] [119] [120] . The first experiments demonstrating a possible role of 11 -HSD1 inhibition in blocking neurotoxicity were performed using primary cultured cells derived from fetal rat hippocampus, and it was shown that CBX inhibition of 11 -HSD1 was able to prevent kainic acid induced neurotoxicity [121] . Further insight was obtained from 11 -HSD-/-animals, showing that aged wild-type animals show GC associated, hippocampal driven, significant learning and memory impairments in the water maze test [122] . Importantly, aged knock-out animals perform not significantly different in these tests than young wild-type or young knockout animals, suggesting that hippocampal 11 -HSD1 inhibition might show significant effects and protects against ageing related loss of cognitive functions [122] . Indeed, in a double-blind, placebo controlled crossover study with healthy volunteers and diabetic patients (age matched, 52-75 years of age), administration of CBX (100 mg/ 3 times/day) resulted in significant improvement of verbal fluency and memory function after 4 weeks of treatment [123] . The recently described rare haplotype discovered in the regulatory region of the HSD11B1 gene [124] was associated with a 6-fold increased risk for sporadic Alzheimer's disease, adding a further piece of evidence to the role of GCs and their metabolic activation in cognitive function. Importantly, an undisclosed compound from a recently developed selective inhibitor series by Merck (unpublished data) shows similar positive effects in animals subjected to passive avoidance or novel object recognition tests, suggesting that applications of selective 11 -HSD1 inhibitors indeed go well beyond the treatment of the metabolic syndrome.
Role of 11 -HSD1 in Glaucoma
Increase in intraocular pressure can be provoked by ocular or systemic administration of GCs, and furthermore, patients with primary open angle glaucoma exhibit increased GC sensitivity [125] [126] [127] . Expression of 11 -HSD1 has been shown in nonpigmented epithelial cells of the ciliary body, the site of aqueous humor production [125] [126] [127] , likely to be the reason for the observed increased cortisol:cortisone ratio in humor. Topical administration of the 11 -HSD inhibitor CBX lowers intraocular pressure in healthy volunteers and patients with ocular hypertension, pointing to a potential novel application for 11 -HSD1 inhibitors [125, 127] .
Inflammation and Immunity: What is the Function of 11 -HSD1 in the Immune System?
Since their introduction into clinical medicine GCs almost 50 years ago [20] GCs have been a cornerstone in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, asthma bronchiale and autoimmune diseases or are used in transplantation settings to prevent graft versus host disease [1] [2] [3] 19, 128] . Consequently, much has been learned about the underlying pathophysiological mechanisms by the use of synthetic GCs. GCs exert potent effects on the immune system and it now appears to be oversimplified that GCs have merely an anti-inflammatory or immunosuppressive profile [129, 130] . The dogmatic viewpoint of immunosuppressive GC action appears to be supported by the fact that GCs have been mainly used in pharmacological i.e. supraphysiological doses. Many recent studies however suggest that the role of GCs on the immune system is extremely complex and shows a time, dose, compound and context dependent pattern of reactions on critical cells of the immune system [129, 130] . It appears that inflammatory processes are regulated in a time dependent manner and controlled by synergistic and antagonistic actions of GCs and cytokines. As discussed in two overviews [129, 130] , GCs upregulate the expression of IL-6 receptors, the signal transduction component gp13, of IL-1 receptors or can promote release of inflammatory signals such as TNF , IL-6 or macrophage migration inhibitory factor [129, 131] . Thus it appears that GC effects are rather immunoregulatory than only immunosuppressive. Furthermore GCs are intimately linked to their capacity to alter specifically the secretion pattern of cytokines associated with inflammatory and immune processes [129] . GCs modify the Th1-Th2 cytokine profile by favouring a Th2 profile and might represent an important determinant for the development of a specific Th1/Th2 pattern in inflammatory situations. Not unexpectedly, 11 -HSD1 is expressed at important sites of inflammatory responses. Whereas peripheral lymphocytes appear to be devoid of 11 -HSD isozymes [132] , enzymatic activity and expression of 11 -HSD1 was noted in stromal cells of lymphoid tissues [133] , in activated monocytes [104] or in dendritic cells [134] . Thus far the use of inhibitors of 11 -HSD enhanced the local effects of GCs in patients with psoriasis or eczema [135] or decreased resistance to experimental Listeria infections [136] . Taken together, modulation of local activation of GC activation in immune tissues by 11 -HSD inhibitors might offer the exciting possibility to selectively drive and direct immune responses [129, 130, 134] , but final proof of concept for this hypothesis is still missing and experiments in several laboratories are currently underway.
Glucocorticoid Induced Osteoporosis: Does 11 -HSD1 Play a Role?
Chronic exposure of endogenous and synthetic GCs has fundamental effects on bone structure and function [137] , with osteopenia, osteoporosis and increased risk for bone fractures as well recognized consequences. These detrimental effects are potentially reversible at least in part, and amenable to treatment e.g. by use of bisphosphonates [138] . GCs exert multiple effects on bone cells, by increasing bone resorption and decreasing bone formation, however the underlying mechanisms are at present far away from being completely understood. The potential impact of 11 -HSD expression in bone cells [26, [139] [140] [141] was addressed in some studies. Short-term inhibition with CBX in healthy volunteers had no effect on bone formation markers, whereas a suppression of bone resorption markers was noted [140] . It was proposed that expression of 11 -HSD1 in osteoblasts affects proliferation and differentiation and due to predominant reductase activity in intact cells constitutes a risk factor in age related decrease in bone formation and increased risk for GC induced osteoporosis [140] . Somewhat surprising was the lack of a clear bone phenotype in the 11 -HSD1-/-mouse model. The animals exhibited no significant changes in cortical or trabecular bone mass, and aged animals show similar levels of bone loss compared to matched control animals [142] , however, a complete absence of bone marrow adipocytes was noted. Clearly further studies are necessary to determine the role of 11 -HSD isozymes and potential pharmacological intervention of 11 -HSD inhibition in bone tissue.
STRUCTURE FUNCTION RELATIONSHIPS: DEVELOPMENT OF SELECTIVE 11 -HSD INHIBI-TORS AND STRUCTURE DETERMINATION OF 11 -HSD1
Since the beginning of 11 -HSD research several natural or synthetic derivatives have been available for proof of concept and even for clinical trials as mentioned above. The most prominent examples have been derivatives of glycyrrhizin, the component of licorice. Most widely used are glycyrrhetinic acid and its hemisuccinate ester carbenoxolone, originally developed for the treatment of peptic ulcer. Other reported natural compound to inhibit 11 -HSD enzymes include flavonoids such as naringenin [143] [144] [145] or endogenous steroids such as pregnane derivatives [146] or bile acids like chenodeoxycholic acid [147, 148] . However, all these compounds are characterized by a lack of selectivity, fairly low efficacy, are not easily amenable to combinatorial chemistry, show unfavorable pharmacochemical properties, or a combination of all.
It is not surprising that the advanced biological and chemical validation of 11 -HSD1 as target in metabolic disease (as outlined above) has initiated significant activities in the pharmaceutical and biotechnology industry. A survey of approved patents reveals that nearly every larger pharmaceutical company has an 11 -HSD1 discovery program and has secured IP positions on compounds for use in the treatment of the metabolic syndrome ( Table 1) . At present three types of compounds have publications demonstrating clinical or biological proof of concept. These include the unselective inhibitor carbenoxolone (CBX) [61, 62, 123, 125] , the arylsulfonamidothiazoles developed by Biovitrum/Amgen [149] and the adamantyltriazoles invented by Merck [25, [95] [96] [97] . Results from clinical trials with any of the synthetic compounds developed have not been made publicly available yet. An interesting concept for inhibitor development was recently presented based on structural classification of natural products followed by combinatorial chemistry, resulting in several 11 -HSD isozyme selective octahydronaphthalene compounds [150] .
Detailed kinetic target characterization [39, 151] patterns. Several of these compounds display low nanomolar affinities for the human enzyme and are highly selective between species orthologs (mouse/human) and 11 -HSD isozymes. This result points to important differences in the active sites of the murine and human enzyme, which obviously determine inhibitor affinity and selectivity (Hult et al.
Most if not all of the initial lead series of inhibitors have been probably developed in the absence of experimental structure information for 11 -HSD1. This is likely due to the biochemical and biophysical properties of the enzyme, posing difficulties in purification and crystallization. Due to the membrane attachment and its hydrophobic properties, purification of the full-length enzyme in its fully functional form, i.e. demonstrating 11-oxo reductase activity, has proven to be difficult and is reportedly achieved by only one group and includes a critical solubilization procedure [152] . Engineering attempts (i.e. removal of transmembrane domain) have been successful [153] to promote soluble protein production and these preparations have been extensively characterized, demonstrating indistinguishable kinetic properties from the full length form ( [151] , Hult et al. # ) . Despite these successes the enzyme prepara-tions still tended to form high molecular weight, soluble aggregates, prohibi-ting successful crystallization, probably due to large hydrophobic surfaces despite removal of the membrane anchor. In our hands, extensive biophysical characterization and optimization of solubility conditions was necessary to obtain enzyme for crystallographic studies as in the case of guinea pig [154, 155] and the human 11 -HSD1 enzyme (Wu et al. unpublished data).
Three structures were deposited with the Protein Data Bank (PDB) nearly at the same time: the structures of guinea pig in complex with NADP+ ( [155] , 1XSE), and two slightly different constructs of human 11 -HSD1, in complex with the detergent CHAPS and NADP+ ( [156] , 1XU7, 1XU9) and the structure of human 11 -HSD1 in complex with NADP+ and CBX (2BEL, Wu et al. unpublished). Later on, the murine structure as complex with NADP and cortisone followed ( [157] , 1Y5R). All structures reveal the typical SDR-type folding pattern with a Rossmann-fold nucleotide binding domain (Fig. 2) and four highly conserved Tyr183, Lys187, Ser170 and Asn143 residues constituting the catalytic center [28, 29] . The important result obtained with the guinea pig structure [155] was the detailed analysis of hydrophobic surface properties, allowing to develop a model for lipid membrane interaction. Importantly, the entrance to the active site is exposed to the lipid bilayer, allowing funneling of hydrophobic substrates such as GCs or oxysterols [155, 158, 159] and explaining apparent kinetic properties [151, 155] . The structure of human 11 -HSD1 in complex with the steroid-like detergent CHAPS [156] is a valuable tool to understand binding and inhibition by 5 -reduced sterols such as bile acids [147] . This construct crystallized in 2 different crystal packings, and the authors suggested a redox-sensitive dimer-tetramer transition as biological mechanism, further mediated by CHAPS or other hydrophobic steroids in the lipid environment [156] , however, the observed crystal contacts appear to be too small to justify a tetrameric state as biological unit. In solution human 11 -HSD1 is clearly a biological dimer [160] . The crystal structure of human 11 -HSD1 in complex with NADP and CBX (2BEL, Wu et al. unpublished) shows for the first time a complex with an inhibitor that has proven biological and clinical significance [61, 62, 123, 127] . The structure allows to determine critical active site features and properties. CBX binds through few polar contacts, namely through a bifurcated bond from CBX-O35 to O2n of the nicotinamide ribose and Oh of Tyr183, and through contacts between CBX-O11 to OH of Ser170 (Fig. 3) . Binding is otherwise driven by shape complementarities to large hydrophobic surfaces (Fig. 3) . Clearly, all these structural efforts have been a breakthrough for pursuing and interpreting structure-activity relationships, and will clearly be instrumental to further improve, predict and interpret inhibitor properties. Fig. (3) . Close up view of the active site showing hydrophobic contact surfaces (yellow mesh) and polar interactions between CBX (green) and residues Tyr183 and Ser170 of 11 -HSD1 and the nicotinamide ribose of NADP+ (blue).
PERSPECTIVES AND COMMENTARY
As discussed in this overview selective inhibition of 11 -HSD1 could in principle offer unprecedented and unique opportunities to improve all symptoms of the metabolic syndrome, which taken together, constitute independent risk factors for the development of cardiovascular disease. Due to the central role of GCs in control of metabolism and the function of 11 -HSD1 as a pre-receptor control of the GR, tissue selective blockade could be a general principle to improve insulin sensitivity, lower lipid levels, regulate fat accumulation and decrease arterial hypertension, the cardinal features of the metabolic syndrome. Clearly, further innovative approaches are needed besides the established pharmacological principles of e.g. PPAR and PPAR agonists to lower lipids or increase insulin sentivity in order to combat the consequences of the world wide dramatic increase in obesity and diabetes. In fact, several of the beneficial effects observed with fibrates or thiazolidine-diones might be due to their potential to downregulate 11 -HSD1 in liver or adipose tissue. Moreover, the tight connection between lipid and glucose metabolism [161, 162] might be linked through the LXR-GR-11 HSD1 axis [111] . Blockade of the hepatic GR to increase insulin sensitivity and lower blood glucose have been shown to be a valid concept in the treatment of diabetes [163] [164] [165] [166] and at least in several animal models a variation of this theme by inhibition of hepatic 11 -HSD1 has been shown effective [82, 83] . Targeting of hepatic 11 -HSD1 might thus be a valid principle in lean diabetic individuals or in a subset of obese patients with elevated hepatic GC reamplification [64] . However, in several, but not all studies of human obesity hepatic expression of 11 -HSD1 is apparently downregulated and might therefore not be the primary target for treatment of insulin resistance and hyperglycemia [167] . In monogenic 11 -HSD1 models, adipocyte 11 -HSD1 plays the central role in mediating features of the metabolic syndrome and therefore might constitute the prime pharmacological target. Human idiopathic metabolic syndrome is undoubtedly more complex in terms of GC amplification [41, 42, [67] [68] [69] [70] [71] [72] [73] . This is further corroborated by a recent mouse model of obesity and insulin resistance [64] , with elevated hepatic 11 -HSD1 activity but decreased adipose 11 -HSD1 levels, indicating that such a pattern of GC amplification might exist in human idiopathic obesity as well. Hence it is clearly mandatory to investigate further patient populations to illuminate the role of GC amplification by 11 -HSD1, determine the status of 11 -HSD1 expression and address the suitability of 11 -HSD1 inhibitor therapy.
Further studies will reveal if 11 -HSD1 inhibition will have an impact in unrelated metabolic states such as osteoporosis, immunity, inflammation or ageing related impairments in humans. Moreover, it is tempting to speculate that 11 -HSD1 might play a role in other side effects observed under high dose GC therapy, e.g development of peptic ulcer. Clearly, concerns regards chronic use of 11 -HSD1 inhibitors need to be addressed. These comprise mainly potential adverse effects on the immune system and on the HPA axis. Undoubtedly within the next years clinical studies will be conducted and made available, and will reveal if GR pre-receptor metabolism constitutes a valid approach for multiple facets of the metabolic syndrome.
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